In addition to CD8+ T cell responses to HLA-I neoantigens, which mediate tumor rejection by direct killing, induction of CD4+ T cell responses to HLA-II neoantigens have been repeatedly reported in preceding neoantigen vaccine clinical trials (2–7, 10, 11). This evidence concerns the gene CD8A and neoplasm.